Endothelin Blockade in Patients With Single Ventricle Physiology
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 12 - Any |
| Updated: | 11/23/2013 |
| Start Date: | May 2010 |
| End Date: | August 2013 |
| Contact: | Jamil Aboulhosn, MD |
| Email: | JAboulhosn@mednet.ucla.edu |
| Phone: | (310) 794-9629 |
Recent studies have shown beneficial effects of sildenafil in patients with single ventricle
congenital heart disease. The purpose of this study is to determine whether Bosentan, a
drug with similar effects, will have similar benefit in this patient population.
Inclusion Criteria:
- At least 12 years of age
- Single ventricle congenital heart disease
- Require cardiac magnetic resonance imaging (MRI) for clinical purposes.
Exclusion Criteria:
- < 12 years of age
- Pregnancy or women who may become pregnant (sexually active and unwilling to use
birth control)
- Patients taking cyclosporin or glyburide
- Patients with baseline liver dysfunction (AST or ALT > 3 times upper limit of normal)
- Contraindications to MRI (including pacemakers)
- Use of Bosentan within one month prior to enrollment
We found this trial at
1
site
UCLA Medical Center Founded in 1955, UCLA Medical Center became Ronald Reagan UCLA Medical Center...
Click here to add this to my saved trials
